Clinical trial
Use Of GW274150 In The Prophylactic Treatment Of Migraine
NCT00242866 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00242866 |
|---|---|
| Title | Use Of GW274150 In The Prophylactic Treatment Of Migraine |
| Official title | A Multicentre, Two-part, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up to 120mg Daily for 12 Weeks in the Prophylactic Treatment of Migraine. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Migraine Disorders |
| Intervention type | Drug, Other |
| Interventions | GW274150, Placebo |
| Enrollment | 430 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Oct 21, 2005 |
| Last update posted | May 9, 2016 |
| Countries | Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: